eIF4B Antibodies

Santa Cruz Biotechnology delivers a wide array of eIF4B monoclonal antibodies for investigating eIF4B in cellular processes. The monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). eIF4B, or eukaryotic translation initiation factor 4B, plays a critical role in the initiation of protein synthesis by facilitating the binding of mRNA to the ribosome. As a key regulator of translation, eIF4B influences cell growth and proliferation pathways. Research has shown that abnormal eIF4B activity is associated with various diseases, including cancer, highlighting its significance as a research target. Understanding eIF4B function can provide valuable insights into cellular regulation mechanisms and disease development. Investigating eIF4B expression patterns helps researchers uncover new therapeutic approaches for translation-related disorders. eIF4B research continues to reveal important connections between protein synthesis and cellular homeostasis. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of eIF4B's role in health and disease.